AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Propanc Biopharma receives US patent for enzyme composition in cancer treatment.
ByAinvest
Wednesday, Sep 17, 2025 8:54 am ET1min read
Propanc Biopharma has received a certificate of grant from the US Patent & Trademark Office for its "proenzyme composition" patent, specifically covering a future clinical dose of its lead asset, PRP. This is the fourth US patent granted by the company, and adds to its intellectual property portfolio of 90 patents filed in major jurisdictions. The patent is an important part of the IP portfolio as the company advances to a Phase 1B, First-In-Human study in advanced cancer patients.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet